TheEdgeResearch
Home / Stocks / CELG-RI

Bristol-Myers Squibb Company Ce (CELG-RI)

NYSE Healthcare Medical - Pharmaceuticals
$0.11 ▲ +0.28%
Market Cap
$220.8M
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Beta
-0.47
52-Wk Range
0.108-0.11
CEO
Christopher S. Boerner
Country
US
Currency
USD

Bristol-Myers Squibb Company Ce operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Princeton, NJ, US. The stock last traded at $0.11, up 0.28% on the session, giving a market capitalisation of $220.8M. On trailing twelve-month figures it carries a net margin of 26.5%. Its beta of -0.47 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
Price / Sales
0.00
Price / Book
0.00
EV / EBITDA
0.00
Gross margin
96.2%
Operating margin
34.0%
Net margin
26.5%
Return on equity
Debt / equity
3.29
Current ratio
2.23
Dividend yield
Payout ratio
0.0%
Company profile
Exchange
New York Stock Exchange
Employees
34,100
IPO date
2019-11-21
Headquarters
Princeton, NJ, US
About Bristol-Myers Squibb Company Ce

Bristol Myers Squibb Company (BMS) operates as a biopharmaceutical enterprise, managing the entire lifecycle of its therapeutic products, from initial discovery and development to manufacturing, marketing, and distribution. Its diverse portfolio includes conventional small molecule drugs, advanced biologics (which are derived from biological processes), and specialized chimeric antigen receptor (CAR-T) cell therapies. The company was established in August 1933 and maintains its corporate headquarters in Princeton, New Jersey.

Comparable companies

Bristol-Myers Squibb Company Ce is most often compared with the following Healthcare names:

AMGNCVSGILDGSKHCAMCKMDTPFESNYVRTX
More research on CELG-RI
CELG-RI technical analysis CELG-RI TheEdge Score Compare against peers
Open full interactive analysis & DCF →